ArticleCurrent medicinal chemistry2026
Classifying Molecular Subtypes and Establishing a Prognosis Model using Oxidative Stress-related Genes for Lung Adenocarcinoma.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionOxidative stress is closely related to the progression of lung adenocarcinoma (LUAD) and its prognosis. This study identified molecular subtypes using oxidative stress-related genes (OSRGs) and applied these genes to establish a prognosis model for LUAD.
methodsLUAD samples were derived from a public database, and OSRGs were acquired from GeneCards database. Molecular subtypes were classified by "Consensus- ClusterPlus" package. We compared overall survival (OS), clinical and immune infiltration features in different subtypes, and screened differentially expressed genes (DEGs) employing the "limma" package. Thereafter, a prognostic OSRG signature was developed via LASSO regression analysis, followed by construction of a RiskScore model and validation of its predictive performance. In vitro cellular assays were conducted to measure the expression of the key genes and analyze their effect on the proliferation, migration, and invasion potentials of LUAD cells. Pathway enrichment analysis in different risk groups was conducted.
resultsWe classified two molecular subtypes (Cluster1, Cluster2) with distinct clinical characteristics, immune cell infiltration, and survival outcomes. Subsequently, 7 prognostic OSRGs DISCUSSION: This study distinguished two molecular subtypes and developed a prognostic RiskScore model with 7 OSRGs for LUAD. However, these findings still require further experimental verification.
conclusionTo conclude, our current research contributed to the precise stratification and treatment of LUAD.
Indexed as
Identifiers
41863163What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.